Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Pediatric Patients with Malignant Disorders

Shalini Shenoy, MD, Barbara Asselin, Jignesh Dalal, Rakesh Goyal, Jonathan L. Kaufman, MD, David Loeb, John McCarty, Kent Robertson, Caron Strahlendorf, Mark C. Walters, MD, Jennifer Angell, Dirk Huebner, MD, Peter J. Shaw, MA, MB, BS, MRCP, FRACP

Blood (2010) 116 (21): 2245.

https://doi.org/10.1182/blood.V116.21.2245.2245

Published: 2010

Journal Articles

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

Ricardo Spielberger, MD, Mary Territo, MD, Simon Durrant, MD, Stephen Nimer, MD, John McCarty, MD, David Hurd, MD, Dietmar Berger, MD, Jeff Aycock, Mon-Gy Chen, Patrick Stiff, MD

Blood (2007) 110 (11): 1664.

https://doi.org/10.1182/blood.V110.11.1664.1664

Published: 2007

Journal Articles

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

Thomas C. Shea, MD, Jeffrey Johnston, MA, William Walsh, MD, Sherif Farag, MD, PhD, John McCarty, MD, Asad Bashey, MD, PhD, Luis Isola, MD, Marc Stewart, MD, Michael Kelly, MA, Kouros Owzar, PhD, Charles Linker, MD

Blood (2007) 110 (11): 486.

https://doi.org/10.1182/blood.V110.11.486.486

Published: 2007

Journal Articles

AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.

Gary Calandra, John McCarty, Joseph McGuirk, Bart Barlogie, Sue-Anne Crocker, Karin Badel

Blood (2006) 108 (11): 5218.

https://doi.org/10.1182/blood.V108.11.5218.5218

Published: 2006

Journal Articles

AMD3100 Plus G-CSF Use in Proven Poor Mobilizers in a Compassionate Use Protocol (CUP).

Joseph McGuirk, MD, John McCarty, MD, Kaaren Gibb, BSc, Karin Badel, BSc, N Gary Bridger, PhD, Gary Calandra, PhD, MD

Blood (2005) 106 (11): 154.

https://doi.org/10.1182/blood.V106.11.154.154

Published: 2005

NARROW

Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Pediatric Patients with Malignant Disorders

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.

AMD3100 Plus G-CSF Use in Proven Poor Mobilizers in a Compassionate Use Protocol (CUP).

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Pediatric Patients with Malignant Disorders

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.

AMD3100 Plus G-CSF Use in Proven Poor Mobilizers in a Compassionate Use Protocol (CUP).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only